Cart
sales@molnova.com
Lupartumab
CAS No. 1640971-88-5
Lupartumab( —— )
Catalog No. M36885 CAS No. 1640971-88-5
Lupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A) and is employed in the synthesis of antibody-active molecular couplers for studying LYPD3-associated tumor diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 739 | In Stock |
|
| 10MG | 1169 | In Stock |
|
| 25MG | 1758 | In Stock |
|
| 50MG | 2316 | In Stock |
|
| 100MG | 3125 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLupartumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionLupartumab (BAY 1112623) is a monoclonal antibody targeting LYPD3 (C4.4A) and is employed in the synthesis of antibody-active molecular couplers for studying LYPD3-associated tumor diseases.
-
DescriptionLupartumab (BAY 1112623) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of antibody-drug conjugate BAY 1129980.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorADC Antibody
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1640971-88-5
-
Formula WeightApproximately 150 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Willuda J, et al. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 May;16(5):893-904.?
molnova catalog
related products
-
Ac-Glutamine
Ac-Glutamine
-
CAY10781
CAY10781 is an inhibitor of the protein-protein interaction between neuropilin-1 (NRP-1) and VEGF-A.1It inhibits the interaction by 43% when used at a concentration of 12.5 μM. CAY10781 also inhibits VEGF-A-induced phosphorylation of VEGFR2 in catecholamine A-differentiated (CAD) cells when used at the same concentration.
-
Prosaikogenin D
Prosaikogenin D is a natural product extracted from the roots of Buleurum bicaule Helm (Apiaceae) with anti-cancer activity.
